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Cyclosporin AProgressive olfactory impairment is one of the earliest markers of neurodegeneration. However, the underlying
mechanism for this dysfunction remains unclear. The present study investigated the possible role of microgliosis
in olfactory deﬁcits using a mousemodel of Niemann–Pick disease type C1 (NPC1), which is an incurable neuro-
degenerative disorder with disrupted lipid trafﬁcking. At 7 weeks of age, NPC1 mutants showed a distinct
olfactory impairment in an olfactory test compared with age-matched wild-type controls (WT). The marked
loss of olfactory sensory neurons within the NPC1 affected olfactory bulb (NPC1-OB) suggests that NPC1
dysfunction impairs olfactory structure. Furthermore, the pool of neuroblasts in the OB was diminished in
NPC1 mice despite the intact proliferative capacity of neural stem/progenitor cells in the subventricular
zone. Instead, pro-inﬂammatory proliferatingmicroglia accumulated extensively in the NPC1-OB as the dis-
ease progressed. To evaluate the impact of abnormal microglial activation on olfaction in NPC1 mice, a
microglial inhibition study was performed using the anti-inﬂammatory agent Cyclosporin A (CsA). Impor-
tantly, long-term CsA treatment in NPC1 mice reduced reactive microgliosis, restored the survival of newly
generated neurons in the OB and improved overall performance on the olfactory test. Therefore, our study
highlights the possible role of microglia in the regulation of neuronal turnover in the OB and provides
insight into the possible therapeutic applications of microglial inhibition in the attenuation or reversal of
olfactory impairment.
© 2014 Elsevier B.V. All rights reserved.β; APP, amyloid precursor pro-
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The olfactory system is an essential sensory element for survival, and
it is primarily based on well-organized neuronal communications
between the olfactory epithelium (OE) and the olfactory bulb (OB).
Every process associated with proliferation, maturation, integration
and apoptosis of OB neurons must be ﬁne-tuned to maintain olfaction
functional integrity [1,2]. Interestingly, the progressive loss of olfaction
is often observed in the initial stages of neurological disorders, including
Alzheimer's disease (AD) [3], Parkinson's disease (PD) [4], dementia and
Down's syndrome [5,6], which suggests that olfactory dysfunction is an
early sign of neurodegeneration [7]. The presence of amyloid-β (Aβ) or
α-synuclein pathology has been linked to this phenomenon [8,9]. How-
ever, the pathological basis of olfactory dysfunction in the neurodegen-
erative process has not been thoroughly explained.
Niemann–Pick disease type C1 (NPC1) is a fatal metabolic disorder
caused by a mutation in the NPC1 gene, which leads to the disruption
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somal and late endosomal compartments [10]. Considering that the
presence of neurological complications is signiﬁcantly correlated with
disease severity [11], elucidating the neurodegenerative process is an
important step to establish therapeutic strategies for NPC1. A patterned
neuropathy has been observed in NPC1-affected humans and mouse
models with distinctive signs of inﬂammation usually triggered by
activation of microglia and/or astroglia [11,12]. Because a neural-
speciﬁc loss of theNPC1 gene is sufﬁcient to reproduce theNPC1 pheno-
type [13], neuronal damage might precede reactive microgliosis and
astrocytosis in NPC1. However, several studies have also shown that a
neural pathology could develop in a non-autonomous manner in
NPC1 [14]. Indeed, intact NPC1 function in astrocytes seems to be im-
portant in supporting neurons in vitro [15], and NPC1 gene-null oli-
godendrocytes fail to maintain proper CNS myelination patterns,
which results in Purkinje cell loss in the cerebellum that resembles
NPC1 pathology [16]. Furthermore, TNF-α, a pro-inﬂammatory cyto-
kine, is involved in NPC1-associated liver damage [17], and anti-
inﬂammatory agents relieve symptoms and increase the life span of
NPC1 mutant mice [18]. Therefore, the role of abnormal microgliosis
and inﬂammation in NPC1 progression still needs to be determined.
Herein, we assessed the pathological changes in olfaction using an
NPC1 mouse model. Our results demonstrated that NPC1 mice showed
distinct signs of olfactory dysfunction in a behavior test compared
with WT controls. Our results also revealed a drastic loss in olfactory
sensory neurons (OSNs) and neuroblasts with excessive microglial
activation in the NPC1-OB. Notably, the administration of the anti-
inﬂammatory drug CsA considerably improved olfactory function and
increased neural survival in NPC1 mice through microglial inhibition.
These data indicate that the regulation of microglial activation might
be important for the treatment of olfactory dysfunction in neurological
disorders.
2. Materials and methods
2.1. Animal model
Breeding pairs of heterozygous NPC1 null mice (Balb/c NPC1NIH;
NPC1) were purchased from Jackson Laboratories (Bar Harbor, MA).
The genotypingwas performed as previously described [19], and homo-
zygous WT and NPC1 mice were used in this study. All animals were
handled in accordance with the regulations of the Institute of Laborato-
ry Animal Resources (SNU-110517-3, Seoul National University, Korea).
No speciﬁc gender-based differences were observed in each experi-
ment. The number of animals used is indicated in the Results section
and ﬁgure legends.
2.2. Buried food ﬁnding test
To evaluate olfaction inmice, the buried food test was used as previ-
ously described [20] with somemodiﬁcations. Brieﬂy, 7-week-old mice
from each experimental groupwere fasted for 24 h before the test. Next,
the mice were individually habituated for 10 min in a new cage with
fresh bedding. During the habituation step, a piece of standard chow
(1 × 1 cm) was buried under the bedding in the middle of a new cage
(test cage) to a depth of 0.5 cm. The subject was then placed in the
left corner of the test cage and allowed tomove freely to seek thehidden
food for 3 min. During this time, all activities, including snifﬂing around
or digging in the bedding,were recorded until themouse discovered the
food and began to eat (latency). If the mouse was unable to locate the
food within 3 min, the result was categorized as a ‘failure’ (Figs. 1B
and 6B) and was also excluded from the mean latency calculations
(Figs. 1C and 6C). Directly after the test, eachmouse underwent another
trial with the food placed on top of the bedding (exposed food test) to
ensure that the buried food testwas based on olfaction and not on visual
ability.2.3. Cyclosporin A (CsA) administration
Chronic microglial inhibition was conducted by CsA treatment
(Chong Kun Dang, South Korea), a broad anti-inﬂammatory drug.
Four-week old NPC1 mice were injected with CsA (5 mg/kg, prepared
in normal saline) every second day for 4 weeks and the control group
received the same volume of normal saline without CsA.
2.4. 5-bromo-2′-deoxyuridine (BrdU) administration
To trace the fate of proliferating cells in the OB, 4-week-old mice
received a single injection of BrdU (Sigma–Aldrich, St. Louis, MO)
(50 mg/kg, dissolved in 0.9%NaCl) intraperitoneally (i.p.) and sacriﬁced
after one month. Meanwhile, the short-term characterization of prolif-
erating cells was achieved by a BrdU injection (100 mg/kg, i.p) into
4- or 8-week-old mice 4 or 24 h before euthanasia. The control sub-
jects received the same volume of normal saline.
2.5. Tissue processing
Tissue preparation was performed as previously described [19]. For
RNAand protein extraction,micewere sacriﬁced by cervical dislocation,
andwhole brainswere immediately collected. Then, OBswere collected
for homogenization with Trizol (Invitrogen, Carlsbad, CA) (for RNA) or
lysis buffer (Pro-prep; Intron Biotechnology, Korea) (for protein)
using a TissueLyser II (Qiagen, Valencia, CA). For immunohistochemis-
try, mice were perfused with normal saline and then with 4% parafor-
maldehyde for 20 min each. The isolated whole brains containing OBs
were post-ﬁxed in 4% paraformaldehyde for another 24 h and trans-
ferred to a 30% sucrose solution for 3–4 days until they sank. In some ex-
periments, the OE was also isolated after perfusion and immersed in a
0.5 M EDTA/10% sucrose solution for decalciﬁcation. Tissues were then
placed into a mold ﬁlled with inﬁltration mixture (OCT compound)
(Sakura Finetek, Japan) and stored at −80 °C until processing for
cryosections.
2.6. Quantitative real time-PCR (qRT-PCR) based gene expression analysis
RNAquantiﬁcation and reverse transcription PCRwere performed as
previously described [19]. qRT-PCR was performed by mixing cDNA
with primers and SYBR Green PCR Master Mix (Applied Biosystems,
Foster City, CA) using an ABI 7500 Realtime-PCR System with the sup-
plied software (Applied Biosystems) according to the manufacturer's
instruction. The primer sequences used in this study were as follows:
Tumor necrosis factor-α (TNF-α), forward 5′-AGGCTGTGCATTGCACCT
CA-3′ and reverse 5′-GGGACAGTGACCTGGACTGT-3′; interleukin-1β
(IL-1β), Forward 5′-GATCCACACTCTCCAGCTGCA-3′ and reverse
5′-CAACCAACAAGTGATATTCTCCAT-3′; IL-6, forward 5′-AAGTGCAT
CATCGTTGTTCATACA-3′ and reverse 5′-GAGGATACCACTCCCAACAG
ACC-3′; and arginase 1 (Arg1), forward 5′-GAACACGGCAGTGGCTTT
AAC-3′ and reverse 5′-TGCTTAGCTCTGTCTGCTTTGC-3′. Each relative
mRNA level was calculated using the comparative Ct method and
then normalized to Glyceraldehyde 3-phosphate dehydrogenase
(Gapdh) mRNA levels.
2.7. Western blot analysis
Protein quantiﬁcation andWestern blot analysis were performed as
previously described [19]. Equal amounts of each protein sample were
loaded onto 8–15% SDS-PAGE gels and then transferred to a nitrocel-
lulose membrane for standard blocking with bovine albumin serum
followed by incubating with primary antibodies. The following pri-
mary antibodies were used: Olfactory marker protein (OMP) (1:500;
Osenses, Australia), Glutamate decarboxylase 65 (GAD65) (1:1000;
Abcam, Cambridge,MA), Tyrosine hydroxylase (TH) (1:1000;Millipore,
Billerica,MA), Calbindin (CBD) (1:1000;Millipore), Doublecortin (DCX)
Fig. 1. Performance of WT and NPC1 mice on buried or exposed food ﬁnding tests. (A) The experimental test design. (B) Individual latencies of WT (n = 20) and NPC1mice (n= 17) to
recover the buried food are shown as stacked bar graphs. Seven NPC1mutants failed to locate the food. (C and D) Mean latencies with buried (C) or exposed food (D). On average, NPC1
mice (n=10) spent almost twice asmuch timeﬁnding the hidden food asWTmice (n=20). Failures (WT: none; NPC1: n=7)were excluded from the calculation. All data represent the
mean ± SEM. ***P b 0.001.
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with peroxidase-conjugated secondary antibodies (1:5000; Zymed
Laboratories Inc., San Francisco, CA) and enhanced-chemiluminescence
reagents (Intron Biotechnology). The relative band density was deter-
mined using ImageJ software (version 1.42q, NIH).
2.8. Immunohistochemistry
The nasal cavity sections (12-μm thick) or whole brain sections
(30-μm thick) were washed with PBS to remove the OCT compound.
Sections were blocked with 5% normal goat serum in PBS and then
transferred to a primary antibody solution. The following primary
antibodies were used: OMP (1:1000; Osenses), Iba1 (1:500; Wako,
Japan), GAP43 (1:500), GAD65 (1:500), BrdU (1:250), and Ki67
(1:250) (all from Abcam); and TH, CBD, DCX and neuronal nuclei
(NeuN) (1:1000; all from Millipore). To detect BrdU- and Ki67-
positive cells, sections were pre-treated with 2 N hydrochloric acid
for 30 min at 37 °C to denature the DNA strands and then neutral-
ized in 0.1 M borate buffer before the blocking step. Primary anti-
bodies and cell nuclei were detected with appropriate Alexa 488-
or 594-conjugated secondary antibodies (1:1000; Molecular Probes,
Eugene, OR) and 4′,6-diamidino-2-dhenylindole dihydrochloride
(DAPI) (Zymed Laboratories Inc.), respectively. Images were cap-
tured with an Eclipse TE200 confocal microscope (Nikon, Japan),
and additional histological analysis followed. No speciﬁc immunore-
activity was observed when the primary or secondary antibodies
were omitted.2.9. Determination of region of interests (ROIs) and histological analysis
Consecutive coronal sections (spaced 180 μm apart) containing the
SVZ were collected to assess the number of proliferating cells in the
SVZ. All BrdU-incorporated cells within the lateral wall of the SVZ
were counted. For histological analysis of the OB, 5 to 6 alternative
representative sagittal sections of the main olfactory bulb region
(500–800 μmlateral to themidline of the left hemisphere) [21]were se-
lected, and the entire region, including the glomerular and granule cell
layers, was captured as shown in Fig. 2A. A total of 8 to 10 appropri-
ate nasal cavity sections per animal were selected according to the
turbinate structure, and each section contained 3 ROIs in the septum,
endoturbinate II and ectoturbinate 2, which was speciﬁed as the
space between the epithelial surface and basal lamina (described in
Fig. 2B).
Cell counting results are expressed as the average number of
immuno-labeled cells per mm2. To determine relative immunoreactivi-
ty, the density of each positive signal within the ROI was measured
using NIH Image J software version 1.63, and the WT value was set at
100%. All analytical procedures were conducted by a researcher blinded
to the experimental conditions, and all experiments used sections that
were carefully matched anatomically between animals.
2.10. OB ﬂow cytometry analysis
To analyze the microglial population in WT and NPC1-OB mice,
8-week old mice were euthanized, and the OB were immediately
Fig. 2.OSNs and other neuron distribution patterns in the OE and OB. (A–D) Representative immunoﬂuorescent images of the distribution patterns of OSNs (OMP+) towards the OB (A),
immature neurons in theOE (GAP43+) (C) and various PGneurons expressing TH, CBD andGAD65 in theOB (D) are shown. The relative immunoreactivity (RI) ofOMP (A), GAP43 (C) and
TH (D) in the NPC1 samples is presented as the percentage ofWT immunoreactivity. In the nasal cavity sections, 3 ROIs (S: septum; 2E: ectoturbinate 2; 2e: endoturbinate) were selected
according to the turbinate structure as indicated in (B). (E) Western blots of neuronal proteins in the whole OBs extracted from the 8-week-old mice support the immunohistochemical
data. A total of 4 and 3 imagesweremerged to complete the entireOB images ofWT andNPC1mice, respectively, in (A). At least 3 animals per groupwere used for immunohistochemistry
and Western blot analysis. Scale bars = 100 μm (A, B and D); 50 μm (C). All data represent the mean ± SEM. ***P b 0.001.
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for 45 min at 37 °C. After ﬁltration through a strainer, cells were in-
cubated with CD11b, CD86 or CD206 antibodies (all from Abcam).
The cells expressing with each marker were detected with an
Alexa 488 secondary antibody (Molecular Probes) and were ana-
lyzed for ﬂuorescence on a FACS Caliber (Becton Dickinson, Franklin
Lakes, NJ, USA).
2.11. Statistical analysis
All data are expressed as the mean ± SEM from independent ex-
periments. For statistical comparisons, Student's t-test and one-way
ANOVA with a Bonferroni post-hoc analysis were performed using
GraphPad Prism (v5.0, GraphPad), and differences were considered
signiﬁcant at P b 0.05.3. Results
3.1. Olfactory impairment in NPC1 mice
Recently, Hovakimyan et al. reported neural defects in theOE andOB
of an NPC1 model [22]. Because axodendritic synaptic activity between
the OE and OB is important in olfactory information processing [23],
we hypothesized that NPC1 mice would exhibit olfactory functional
deﬁcits. To conﬁrm this hypothesis, we conducted a buried food pellet
assay and recorded the latency to discover and begin eating the hidden
food (Fig. 1A).Micewere assessed at 7 weeks of age (representative of a
symptomatic stage), and all subjects showed normal locomotion during
this test. Remarkably, NPC1 mutants (n = 17) performed the test
less efﬁciently than WT mice (n = 20), and 41% of the NPC1 mice
failed to ﬁnd the pellet within the 3 min cut-off time, but all WT mice
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approximately 55 s to ﬁnd the food, and the majority of them (65%)
began to eat the foodwithin 1min (Fig. 1B and C). In contrast, the aver-
age latency for NPC1 mice to ﬁnd the hidden pellet (n = 10, excluding
failed attempts) was approximately 114 s (Fig. 1C). Considering that
neither WT nor NPC1 mice had difﬁculty locating the exposed food
(Fig. 1D), our ﬁndings indicate that olfaction is impaired in NPC1 mice.
3.2. OSN degeneration and a decline in neuronal survival in the OB of NPC1
mice (NPC1-OB)
We visualized neuronal distribution patterns in the OE and OB using
immunohistochemistry, which assessed the impact of NPC1 dysfunc-
tion on olfactory structures. As previously described [22], a considerable
reduction in axonal inputs of the OSNs (OMP+ cells) towards the OB
was detected in 8 week-old NPC1 mice compared with WT mice
(Fig. 2A). We next examined the neuronal precursor population within
the OE, which is responsible for OSN regeneration, and found that the
immature neuronal pool (GAP43+ cells) was reduced in the NPC1-OE
comparedwith theWT-OE (Fig. 2B and C). Moreover, anti-TH reactivity
of periglomerular neurons in the glomerular layer (GL) of the OB was
noticeably decreased in NPC1 mice (Fig. 2D), and immunoblotting
analysis of OB proteins extracted from 8 week-old mice conﬁrmed our
histological ﬁndings (Fig. 2E).
Odor input from OSNs in the OE is further processed in the OB
through reciprocal neuronal actions [23,24]. Themajority of OB neurons
are local granule neurons that reﬁne incoming signals, and they are con-
tinuously replenished by subventricular zone (SVZ)-derived newborn
cells throughout life [25]. To evaluate the capacity of neuronal turnover
in the OB, we investigated the distribution pattern of neuroblasts in the
OB using immunoﬂuorescent staining for DCX, a neural precursor
marker. As shown in Fig. 3A and B, a signiﬁcant reduction in DCX immu-
noreactivity was observed in the OB of 8-week-old NPC1 mutants,
which suggests that the production of neuroblasts in the SVZ and/or
the survival of newborn neurons are defective in the SVZ-OB axis of
NPC1 mice. Next, we used a BrdU tracking technique to clarify the
cause of neuroblast loss in the NPC1-OB. NPC1 and WT mice received
a BrdU injection at 4 or 8 weeks of age and were sacriﬁced after 24 h
to label the proliferative cell population in the SVZ, and some of the
4 week-old subjects were analyzed 4 weeks later to evaluate the survival
rate of newborn cells in the OB. Interestingly, no signiﬁcant differences
were observed in the BrdU incorporation rate of newborn SVZ cells after
a 24-h BrdU pulse between NPC1 and WT mice at both 4 and 8 weeks
of age, which implies that the proliferative capacity of neural precursor
cells in the SVZ is primarily intact in NPC1 mice even during late disease
stages (Fig. 3C and D). Four weeks after a BrdU injection, however, the
number of newly generated mature OB neurons (NeuN/BrdU double-
positive cells) labeled at 4 weeks of age in NPC1 mice was reduced by
approximately 50% comparedwithWTmice (Fig. 3E). Further immuno-
histochemical analysis revealed an increase in the number of cells un-
dergoing apoptosis (activated caspase 3-positive cells) in the NPC1-OB
(Fig. 3F). Therefore, our data suggest that a decreased newborn neuro-
nal survival rate is responsible for the loss of neuroblasts, which ulti-
mately impede proper neuronal turnover in the OB of NPC1 mice.
3.3. Abnormal microgliosis is highly activated in the NPC1-OB
Because NPC1 progression is accompanied by enhanced inﬂam-
mation [26], we next examined the number and activation state of
microglia in the WT- and NPC1-OB using Iba1 immunostaining. At
4 and 8 weeks of age, NPC1 mice showed a remarkable increase in
the total number of microglial cells in the glomerular layer (GL) and
granule cell layer (GCL) (ratio to WT control: 1.8 at 4 weeks and
2.21 at 8 weeks in the GCL; 1.38 at 4 weeks and 1.84 at 8 weeks in the
GL, P b 0.001) (Fig. 4A–C). We also found that amoeboid-like reactive
microglia accounted for a signiﬁcant portion of the total Iba1+ cellpopulation in the NPC1-OB, whereas the majority of Iba1+ cells in the
WT-OB were in a resting state (Fig. 4A′ and A″). Thus, we distinguished
the phenotype of activated microglia within the OB between M1
(pro-inﬂammatory) andM2 (anti-inﬂammatory) types based on sig-
nature gene expression patterns using real-time PCR.We observed that
the gene expression levels of IL-1β and TNF-α, whichwere used as rep-
resentative genes for theM1 typemicroglia, were signiﬁcantly elevated
in the NPC1-OB at 8 weeks of age, but the expression of the M2marker
Arg1 was similar in WT and NPC1 mice (Fig. 4D). Flow cytometry anal-
ysis of the entire microglial population within the OB conﬁrmed these
observations. Most NPC1-derived microglia were labeled with a CD86
marker, indicating a M1 microglial phenotype, but some cells were
identiﬁed as CD206+, a M2 microglial phenotype marker (Fig. 4E).
Overall, these data clearly demonstrate that the abnormal neurotoxic
activation of microglia occurs in the NPC1-OB.
3.4. Disrupted neuronal integrity with enhancedmicrogliosis in the NPC1-OB
Next, we conducted an in vivo BrdU cell tracking assay to quantitate
on-going microgliosis. Four week-old NPC1 and WT animals received a
single intraperitoneal BrdU injection 4 h before perfusion to detect the
rapidly proliferating cell population, which would be largely microglia.
Immunohistochemical analysis revealed that the majority of BrdU+
cells (N90%) within the OB were co-immunostained with Iba1, as
expected (Fig. 5A). Importantly, the number of BrdU/Iba1 double-
positive cells in NPC1 mutants was signiﬁcantly increased, by more
than seven-fold, compared with WT controls, implying the presence of
extensive microgliosis in the NPC1-OB (Fig. 5A).
We further investigated the total amount of accumulated microglial
cells in the NPC1-OB using a 4 week-long BrdU cell tracking technique,
as described in Section 3.2. Immunohistochemical analysis revealed that
the total number of BrdU+/Iba1+ cells in theNPC1-OBwas approximate-
ly three-fold higher compared with the WT control (Fig. 5B). In the
WT-GCL, approximately 80% and 10% of BrdU+ cells differentiated into
NeuN+ mature neurons and Iba1+ microglia, respectively (Fig. 5C). In
the mutant GCL, however, only half of the BrdU incorporated cells
expressed NeuN, whereas Iba1+ cells accounted for over 30% of the
newly generated cells (Fig. 5C). Therefore, we infer that olfactory deﬁcits
are related to the presence of persistent reactive microgliosis and
decreased neuronal turnover in the OB of NPC1 mice.
3.5. Microglial inhibition with cyclosporin A (CsA) improves olfaction in
NPC1 mice
Wedecided to suppressmicroglial activity in the NPC1-OBwith CsA,
a powerful immunosuppressant, to evaluate its therapeutic potential to
restore olfaction. NPC1 mice received CsA (n = 19) or normal saline
(n = 22) injections (i.p) for a total of 4 weeks beginning at 4 weeks
of age, and then microglial activity in the NPC1-OB was examined
using immunocytochemistry. We found that a 4-week-long CsA treat-
ment signiﬁcantly reduced the number of OX-42+ cells, which repre-
sent activated microglia, throughout the NPC1-OB (Fig. 6A). Next, we
performed the buried food testwith all subjects at 7 weeks of age to de-
termine whether CsA improved olfactory dysfunction in NPC1 mice.
Continuous CsA injections contributed to an overall improvement in
the olfaction of NPC1mice, but it had no effect on olfactory performance
of WT mice (Fig. 6B and C). Indeed, the mean latency of saline-injected
NPC1mice did not differ from the untreated NPC1mice shown in Fig. 2;
however, NPC1mice treatedwith CsA showed a tendency to ﬁndpellets
faster than the controls (Fig. 6B and C).
The amelioration of olfactory dysfunction in CsA-treated NPC1 mice
may be due to the protection of OE or OB neurons by attenuated
microgliosis. Notably, CsA administration slightly increased both the
intensity of GAP43-positive areas within the OE (Fig. 7A) and OMP ex-
pression levels in the OB (Fig. 7B). However, the protection of neural
precursor cells and OSNs in the NPC1-OE might not be sufﬁcient to
Fig. 3.Decreasedneuroblasts and neuronal survival in theNPC1-OB. (A) Immunohistochemical images of neuroblasts (DCX+) andRI quantiﬁcation of theDCX-positive area of theWT- and
NPC1-OB at 8 weeks of age. (B) Indirect quantiﬁcation of the neuroblast population by Western blotting also implies decreased neurogenesis in the 8 week-old NPC1-OB. (C and D) To
evaluate the on-going neurogenic activity in the SVZ, 24 h of BrdU cell tracking was conducted inWT and NPC1mice at 4 weeks (C) or 8 weeks (D) of age. The total number of BrdU in-
corporated cells in the SVZ was not affected by NPC1 dysfunction. (E) The fate of SVZ-derived newborns was traced with BrdU for 4 weeks and analyzed using immunohistochemistry.
BrdU+ cells and BrdU+/NeuN+ cells are indicated by asterisks and arrows, respectively. (F) Representative confocal images indicating apoptotic cells (Act.cas3+) in the WT- and
NPC1-OB. At least 3 animals per group were used for immunohistochemistry and Western blot analysis. Scale bars = 50 μm (A, C, D, E and F); 10 μm (magniﬁed square images in E).
All data represent the mean ± SEM. **P b 0.01 and ***P b 0.001.
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tion because the OMP intensity in the CsA-treated NPC1-OBwas approx-
imately 50% of the WT-OB (Fig. 7B). Conversely, continuous CsA
injections readily increased the total number of DCX+ cells by approxi-
mately 66% in the GL (Fig. 7C). To understand the cause of this cellular in-
crease, we ﬁrst labeled proliferating cells with BrdU for 24 h on the lastday of CsA or normal saline treatment and compared the SVZ neurogenic
capacity in CsA-treated and control NPC1mice. No difference in the num-
ber of BrdU-positive cells was observed between the two groups, indicat-
ing that the proliferation of neural stem/progenitor cells was not affected
by CsA treatment (Fig. 7D). We then investigated whether microglial
inhibition provided the positive effect on neuronal survival followed by
Fig. 4.Neurotoxic (M1 type)microglia accumulation in the NPC1-OB. (A) The distribution patterns of microglia in the OB are visualized using Iba1 immunohistochemistry. Representative
magniﬁed images of resting (A′) and activated (A″) are also shown. (B and C) The total number of Iba+ cells in the GL (B) and GCL (C)was quantiﬁed. (D)mRNA expression analysis of the
representative microglial activation markers, including IL-1, TNF-α, and Arg1 in the OB of WT and NPC1 mice (n = 3 for each group), was performed by real-time PCR. Each sample was
tested in triplicate, and one mean WT value (randomly chosen) was standardized as 1 for convenience. (E) For the characterization of microglial phenotypes in the WT- and NPC1-OB,
dissociated microglia were conjugated with CD11b (pan-microglial marker), CD86 (M1 marker) and CD206 (M2marker) and analyzed using ﬂow cytometry. Four images were merged
to complete the entire OB images ofWT and NPC1mice in (A). At least 4 animals per groupwere used for immunohistochemistry and ﬂow cytometry. Scale bars= 100 μm(A); 10 μm(A′
and A″). All data represent the mean ± SEM. ***P b 0.001.
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received a single BrdU injection on the ﬁrst day of CsA or normal saline
administration, and BrdU+ cells were further stained 4 weeks later for
the expression of the neuronal marker NeuN. The fraction of BrdU incor-
porated cells derived from the SVZ that gave rise to mature granule neu-
rons in the GCL increased approximately 1.5-fold in the CsA-treated
NPC1-OB compared with normal saline controls (Fig. 7E). Moreover, the
proportion of apoptotic neurons decreased after CsA administration
(Fig. 7F), implying that excessive microglial activity is related to the loss
of interneurons in the NPC1-OB.4. Discussion
Olfactory dysfunction has been considered as an important determi-
nant of neurodegeneration because it precedes other neurological
symptoms during the neurodegenerative process. In this study, we
elucidated the role of excessive microglial activation, an often observed
phenomenon in the damaged brain, in olfactory impairment using an
NPC1 mouse model. Importantly, microglial accumulation in the OB
reduced the population of OB interneurons by regulating the survival
and apoptosis of granule neurons, which aggravates olfactory loss.
Fig. 5. Reactive microgliosis in the NPC1-OB. (A) To analyze on-going microgliosis, 4 h of BrdU cell tracking were performed in 4 week-old NPC1 andWT animals. In the representative
confocal images, BrdU+ cells and BrdU+/Iba+ cells (rapid proliferatingmicroglia) are indicated by asterisks and arrows, respectively. (B andC) Four-week-oldWT andNPC1mice received
a BrdU injection and were sacriﬁced 4 weeks later for long-term newborn cell tracking. Representative confocal images of newly generated microglia (BrdU+/Iba1+ cells) (B) and
the comparison of the proportion of newborn neurons and microglia in the GCL of the WT- and NPC1-OB (C) show a noticeable bias towards microglial expansion in the NPC1-OB.
BrdU+ cells and BrdU+/Iba+ cells are indicated by asterisks and arrows, respectively. At least 4 animals per group were used for immunohistochemistry. Scale bars = 50 μm (A and
B); 10 μm (magniﬁed square images in B). All data represent the mean ± SEM. *P b 0.05 and **P b 0.01.
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olfactory impairment in neurodegeneration.
Mutations in the NPC1 genes lead to the systemic disruption of lipid
trafﬁcking. However, a pronounced neuropathology, such as tremor,
ataxia and dementia, is one of the most important NPC1 features be-
cause it is ultimately responsible for most patient deaths [11]. Herein,
we performed an olfactory behavior test that shows distinctive signs
of olfactory impairment in NPC1 mice. Progressive neuronal loss in the
olfactory complex of NPC1 mice is likely responsible for the deﬁcit be-
cause we observed signiﬁcant reductions in the pool of OSNs in NPC1
mice, as previously described [22]. Interestingly, the over-expression
of the amyloid precursor protein (APP) accelerates the synthesis of
soluble Aβ and leads to aberrant axonal targeting and elimination of
OSNs [27,28]. Considering that impaired lipid metabolism in NPC1
causes an abnormal processing of APP and Aβ accumulation [29], it is
possible that OSN loss is induced by APP- and Aβ-mediated cytotoxicity
in NPC1mice. In addition, based on our previous ﬁndings indicating that
self-renewal and differentiation potency are impaired in neural stem
cells in NPC1 mice both in vitro and in vivo [30,31], NPC1 mouse-
derived olfactory stem cells might also have a defect in the regenerative
capacity compared with WT cells. Although our present study reveals a
reduced pool of OE-residing neuroblasts in NPC1 mutants, which mayprovide evidence for this hypothesis, further investigations focused on
OE-related pathology are necessary to delineate the underlyingmecha-
nisms of OSN degeneration in NPC1 mice.
Postnatal microgliosis lasts for approximately 4 weeks in the rodent
OB, thenmicroglia gradually transform into a resting state and provide a
constant surveillance system for the maintenance of normal brain
functions [32]. However, our results suggest that persistentmicrogliosis
develops in the NPC1-OB, which is also found in other brain regions
[26]. Interestingly, the induction of TNF-α secretion after olfactory
bulbectomy prevents the proliferation of OE neuroblasts and OSN re-
generation and the following olfactory loss in mice [33,34]. Therefore,
the resolution of inﬂammation can be a key treatment strategy for
olfactory dysfunction. In this context, we investigated the beneﬁt
of microglial inhibition to olfaction-related pathology in NPC1 mice.
Similarly, microglial suppression using the anti-inﬂammatory agent
CsA enhanced OSN regeneration by increasing the pool of neural
progenitor cells in the NPC1-OE. However, the protective effects of
CsA might be not enough to compensate for the loss of OSNs because
the axonal inputs of OSNs towards the NPC1-OB are still insufﬁcient
after CsA treatment when compared with theWT-OB. Thus, we suggest
that microglial activity does not play a leading role in OSN degeneration
in NPC1. Our data support previous observations showing that
Fig. 6. CsA treatment inhibitsmicrogliosis and reduces olfactory impairment. To suppressmicroglial activation, CsAwas injected everyother day for onemonth in 4-week oldmice. (A)OX-42
immunostaining and its density analysis show that CsA administration could inhibit extensive microgliosis in the NPC1-OB. (B and C) CsA-treated NPC1 mice (CsA Tx., n = 19) show
improved performances in the buried food test compared with the normal saline treated group (CsA Cont., n = 22). Failures (CsA Tx.: n = 4; CsA Cont.: n = 8) were excluded from the
calculation for (C). Continuous injection of CsA had no effect on the olfactory performance of WT mice (WT Cont.: n = 10). Four animals per group were used for immunohistochemistry.
Scale bars = 50 μm (A). All data represent the mean ± SEM. *P b 0.05, **P b 0.01, and ***P b 0.001.
Fig. 7.Microglial inhibition improves newly generated neuron survival. (A, B and C) Representative OE and OB images of GAP43 (A), OMP (B) and DCX (C) in NPC1 mice after a 4-week
administration of normal saline or CsA. (D) A 24-h BrdU pulse in 4-week-old mice revealed that neurogenic activity in the SVZ was not altered by suppression of microglial activity.
(E) Immunohistochemistry and counting analysis of newly generated mature neurons (BrdU+/NeuN+) in the control- and CsA-treated NPC1-OB demonstrate the beneﬁcial effects of
microglial inhibition on neurogenesis. BrdU+ cells and BrdU+/NeuN+ cells are indicated by asterisks and arrows, respectively. (F) To detect apoptotic OB neurons, immunoﬂuorescent
double labeling of activated caspase 3 (Act.cas3) andNeuNwas conducted. Act.cas3+ cells andAct.cas3+/NeuN+ cells are indicated by asterisks and arrows, respectively. At least 4 animals
per groupwere used for immunohistochemistry. Scale bars = 50 μm (A, B, C, D, E and F); 10 μm (magniﬁed square images in E). All data represent themean± SEM. *P b 0.05, **P b0.01,
and ***P b 0.001.
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microglial-independent manners [35]. However, controlling microglial
activitymay be an important aspect of olfaction becausemicroglial inhi-
bition might positively inﬂuence the survival of interneurons in the
SVZ-OB axis of NPC1mice. These data are consistentwith previousﬁnd-
ings showing that neighboring microglia can alter neuronal network
composition by regulating the neural precursor population in neuro-
genic centers through phagocytosis in intact and aged/diseased brains
[36,37]. Microglia can also induce neural death by secreting neurotoxic
molecules, such as reactive oxygen species or pro-inﬂammatory cyto-
kines, especially in pathological situations [38]. Similarly, we revealed
that subsequent microglial inhibition using CsA restored neuroblast
survival and reduced the number of apoptotic granule neurons, proving
the negative impact of massive microgliosis on the maintenance of the
OB neuronal population.
The presence and physiological meaning of continuous neural
replacement in the OB is under debate [39,40]. In most mammals,
SVZ-derived neural precursor cells migrate through the rostral migrato-
ry stream to the OB, where they then differentiate into granule neurons
[41–43]. Notably, normal olfactory function is disturbed by ablation of
neurogenesis in mice infused with the antimitotic drug AraC [42] and
in the neural cell adhesion molecule gene knock-out mice [44]. These
observations suggest the signiﬁcance of neurogenic activity in the
SVZ-OB axis in olfaction. However, no reliable evidence of neurogenic
activity in the human SVZ has yet been uncovered [39,45], and
Bergmann et al. have indicated that OB neurons exist from birth
throughout life without replacement using C14 concentration analysis
[45]. Therefore, the loss of OB interneurons might be more critical in
humans compared with other species because the maintenance of OB
neuronal projections to other structures is important in olfaction [2].
In this respect, we infer that microglial activity would have a close
relationship with the development of olfactory dysfunction during
neurodegenerative processes in humans as well as in other species by
regulating the survival of OB granule neurons. Indeed,we demonstrated
that CsA treatment considerably reduced the number of mice that
failed to locate the hidden food and decreased the latency to ﬁnd the
pellet. Our data somewhat contrast a previous work that found that
minocycline-inducedmicroglial inhibition had no effect on the recovery
of olfactory dysfunction in a Dichlobenil-induced OB damage model
[46].We speculate that these different outcomes ofmicroglial inhibition
may be attributed to the differences in olfactory damage between these
two models. Dichlobenil induces acute necrosis within the olfactory
mucosa accompanied by a severe reduction in the OSN population
[46], whereas NPC1 dysfunction tends to cause a gradual OSN loss in a
time-dependent manner. Therefore, the beneﬁt of microglial inhibition
might be insufﬁcient to overcome the drastic olfactory impairment in
the Dichlobenil-treated model. To conﬁrm this hypothesis, it would be
worthwhile to determine the therapeutic effects of microglial inhibitors
in a mildly damaged neurodegenerative model.
5. Conclusion
Overall, we emphasize the role of OB microglia in the development
of olfactory dysfunction in NPC1 mice. Present microglial inhibition
studies reveal that abnormal microgliosis may aggravate olfactory
damage, creating the possibility of therapeutic applications for anti-
inﬂammatory agents in patients with neurological disorders who ex-
hibit olfactory impairment. Our work also emphasizes the importance
of bidirectional interactions between neurons and microglia in neuro-
degenerative processes.
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